| Compounds | Topics | Title | Date |
|---|---|---|---|
| cannabis | pain,anxiety,sedative,migraine in humans via survey (n=1513) | Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep | Apr 2019 |
| Positive In conclusion, a majority of patients reported using less opioids as well as fewer medications to treat anxiety, migraines, and sleep after initiating MC. A smaller portion used less antidepressants or alcohol. | |||
| CBD | anxiety in humans via review | Cannabidiol as a Potential Treatment for Anxiety Disorders | Sept 2015 |
|
Action Pathway: CB1,5HT1A Positive Preclinical evidence conclusively demonstrates CBDs efficacy in reducing anxiety behaviors relevant to multiple disorders, including PTSD, GAD, PD, OCD, and SAD, with a notable lack of anxiogenic effects. CBDs anxiolytic actions appear to depend upon CB1Rs and 5-HT1ARs in several brain regions; however, investigation of additional receptor actions may reveal further mechanisms. | |||
| Nerolidol | anxiety in mice via placebo trial | Assessment of anxiolytic effect of nerolidol in mice | Jul 2016 |
|
Ingestion Method: 12.5, 25, and 50 mg/kg Our findings indicated that nerolidol exerts an anxiolytic effect without altering the motor coordination. | |||
| CBD | ptsd,anxiety,insomnia in humans via case study (n=1) | Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report | Oct 2016 |
|
Ingestion Method: 25mg bedtime, 6mg-12mg spray for anxiety Positive Although studies have demonstrated the calming, anti-inflammatory, and relaxing effects of CBD, clinical data from actual cases is minimal. This case study offers evidence that CBD is effective as a safe alternative treatment to traditional psychiatric medications for reducing anxiety and insomnia. | |||
| Myrcene,Caryophyllene | anxiety in humans via experiment (n=5) | Cannabis Essential Oil: A Preliminary Study for the Evaluation of the Brain Effects. | Jan 2018 |
| These results suggest that the brain wave activity and ANS are affected by the inhalation of the EO of Cannabis sativasuggesting a neuromodular activity in cases of stress, depression, and anxiety. | |||
| CBD | anxiety,sleep in humans via study (n=72) | Cannabidiol in Anxiety and Sleep: A Large Case Series | Jan 2019 |
|
Ingestion Method: 25 mg/d to 175 mg/d Current understanding of the physiology and neurologic pathways points to a benefit with anxiety-related issues. The results of our clinical report support the existing scientific evidence. In our study, we saw no evidence of a safety issue that would limit future studies. In this evaluation, CBD appears to be better tolerated than routine psychiatric medications. | |||
| cannabis | anxiety,pain,depression in humans via survey (n=3341) | The Association between Cannabis Product Characteristics and Symptom Relief | Feb 2019 |
| Patients showed an average symptom improvement of 3.5 (SD = 2.6) on an 11-point scale across the 27 measured symptom categories. Dried flower was the most commonly used product and generally associated with greater symptom relief than other types of products. | |||
| Linalool | anxiety,insomnia,epilepsy in mice | Anxiolytic and sedative effects of extracts and essential oil from Citrus aurantium L. | Dec 2002 |
| The results obtained with EOP in the anxiety model, and with EOP, HF and DF in the sedation model, are in accord with the ethnopharmacological use of Citrus aurantium L., which could be useful in primary medical care, after toxicological investigation. | |||
| Myrcene | anxiety,sedative in mice via experiment | Central effects of citral, myrcene and limonene, constituents of essential oil chemotypes from Lippia alba (Mill.) N.E. Brown | Nov 2004 |
|
Ingestion Method: 100 and 200 mg/kg Our study showed that citral, limonene and myrcene presented sedative as well as motor relaxant effects. | |||
| Linalool | anxiety in mice via experiment | Anxiolytic-like effects of inhaled linalool oxide in experimental mouse anxiety models. | Dec 2011 |
|
Ingestion Method: linalool oxide (0.65%, 1.25%, 2.5% and 5.0% w/w) Thus, inhaled linalool oxide was found to have anxiolytic properties in both animal models, without causing any motor deficit. These results suggest that inhalation of linalool oxide may be a useful means of counteracting anxiety. | |||
| Limonene | anxiety in mice via experiment | Anxiolytic-like activity and GC-MS analysis of (R)-(+)-limonene fragrance, a natural compound found in foods and plants | Jan 2013 |
|
Ingestion Method: inhaled 1% These data suggest possible connections between the volatility of (+)-limonene and its anxiolytic-like effect on the parameters evaluated in the elevated plus maze test. The data indicate that (+)-limonene could be used in aromatherapy as an antianxiety agent. | |||
| CBD | anxiety,stress in mice via experiment | The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system | Jul 2013 |
|
Ingestion Method: 30 mg/kg i.p. Action Pathway: CB1 These findings support that the anxiolytic effect of chronic CBD administration in stressed mice depends on its proneurogenic action in the adult hippocampus by facilitating endocannabinoid-mediated signalling. | |||
| cannabis | pain,sedative,anxiety in humans via survey (n=628) | Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. | Nov 2013 |
| Positive Across medical conditions respondents reported using cannabis to effectively address diverse symptoms. Results indicate a substantial disconnect between the therapeutic use of cannabis and research on the risks and benefits of such use; particularly with regard to the anxiolytic and sedative use of cannabis. | |||
| Caryophyllene | depression,anxiety in mice | Beta-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice | Aug 2014 |
|
Ingestion Method: 50mg/kg Taken together, these preclinical results suggest that CB2 receptors may provide alternative therapeutic targets for the treatment of anxiety and depression. The possibility that BCP may ameliorate the symptoms of these mood disorders offers exciting prospects for future studies. | |||
| cannabinoids | anxiety,stress in rats via review | Endocannabinoids and striatal function: implications for addiction-related behaviours. | Feb 2015 |
| In this article we integrate and discuss recent findings in rodents showing selective pharmacological modulation of impulsivity and anxiety by cannabinoid agents. We highlight the potential of selective inhibitors of endocannabinoid metabolism, directed at fatty acid amide hydrolase and monoacylglycerol lipase, to reduce anxiety and stress responses, and discuss novel mechanisms underlying the modulation of the endocannabinoid system, including the attenuation of impulsivity, anxiety, and drug reward by selective CB2 receptor agonists. | |||
| Cymene | anxiety in mice | Pharmacological evaluation of the anxiolytic-like effects of Lippia graveolens and bioactive compounds. | Dec 2017 |
|
Ingestion Method: Lippia graveolens Kunth After administration of the extracts and bioactive compounds, a significant anxiolytic-like response from 1 mg/kg, i.p. was observed, resembling the effect of diazepam. | |||
| CBD | anxiety in humans via placebo trial (n=57) | Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. | Jan 2019 |
| Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS scores were observed between groups receiving CBD 150 mg, 600 mg and placebo. | |||
| cannabis | pain,anxiety,depression in humans via review | Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis | Jun 2019 |
| Positive Meta-analytic results indicated that pain (64%), anxiety (50%), and depression/mood (34%) were common reasons for medical cannabis use. No evidence for publication bias was detected, despite heterogeneity in prevalence rates. | |||